Download The Article
Strategies for Advancing Idiopathic Pulmonary Fibrosis Clinical Development
Strategies for Advancing Idiopathic Pulmonary Fibrosis Clinical Development
Article:
Accelerating IPF Clinical Trials
Overcoming Challenges in Recruitment and Endpoints
IPF affects over 80,000 people in the United States, yet clinical trials face significant challenges due to the rare patient population, unpredictable disease progression, and variability in endpoints. To ensure the successful execution of clinical trials in IPF, partnering with a CRO that has relevant operational, regulatory, and medical expertise is crucial for mitigating risk.
Download this new article to explore site selection and recruitment strategies, patient-centric trial design, and endpoint protection for forced vital capacity (FVC), high-resolution computed tomography (HRCT), and patient-reported outcomes (PROs).
Respiratory CRO
An Industry Leader in Respiratory Clinical Development
Drive the successful execution of complex respiratory clinical trials with a full-service partner that combines proactive communication, early strategic planning, and deep experience engaging with global regulatory authorities.
Medpace’s specialized, cross-functional team of experts bring extensive experience in designing and executing global trials in respiratory and rare diseases. Our hands-on medical leadership and integrated laboratories provide the scientific rigor and operational efficiency required to address respiratory trial complexities and help accelerate your path to approval.
